Popular Articles
Cellulite Treatment

Early Switch From Cyclosporine To Sirolimus After Renal Transplantation Produces Sustained Improvement In Renal Function
BOSTON - Favorable 12-month outcomes are maintained through 30 months of follow-up when renal transplant patients are converted from a cyclosporine (CsA)-based regimen to a sirolimus (SRL)-based regimen three months post-transplant, according to results of the CONCEPT study announced here at the American Transplant Congress (ATC) 2009.
generic viagra online
Study Identifies Biomarker That Safely Monitors Tumor Response To New Brain Cancer Treatment; Paves The Way To Phase 1 Clinical Trial
A specific biomarker, a protein released by dying tumor cells, has been identified as an effective tool in an animal model to gauge the response to a novel gene therapy treatment for glioblastoma mulitforme. The finding, reported in the July 1 issue of Clinical Cancer Research, paves the way for a Phase 1 clinical trial expected to begin in late 2009.
News of the day
Altair Therapeutics Reports Successful Completion Of Phase I Study Of Inhaled AIR645
Altair Therapeutics, Inc., a privately-held, biopharmaceutical company developing novel therapeutics for respiratory diseases, reported results from its phase I study evaluating the safety, tolerability and pharmacokinetics of its lead product, once-weekly inhaled AIR645, in healthy volunteers. AIR645 is a non-steroidal dual inhibitor of cellular responses to interleukin (IL)-4 and IL-13, cytokines that play a critical role in development and progression of asthma, rhinitis and other allergic disorders. Results presented today at the 2009 International Conference of the American Thoracic Society (ATS) within the Mini-Symposium "New Treatment Approaches for Asthma and Allergy" showed that inhaled AIR645 was safe, well tolerated and had dose-dependent exposure in the airways. These results demonstrate the potential of AIR645 as a convenient once-weekly treatment for asthma and other respiratory disorders. Later this year, Altair plans to initiate a phase II efficacy study in patients with asthma.
Cardiovascular

Interest Groups Crowd Airwaves, Pursue Lawmakers

"The increasingly heated fight over health-care legislation is saturating the summer airwaves, with groups on all sides of the debate pouring tens of millions of dollars into advertising campaigns designed to push the cause of reform forward, slow it down or stop it in its tracks," the Washington Post reports. So far, drug makers, labor groups, Democrats and Republicans - among others - have spent $52 million to finance the ad campaigns, a heady start that could lead to a "record-breaking legislative battle." "Much of the spending has been focused on national cable news and the local Washington market, the best way to reach policymakers and opinion leaders in the capital. But as members of Congress leave for August recess, advertising money will follow them, as the target audience for health-care messages shifts from inside to outside the Beltway," the Post reports (Pershing, 8/5). The many interest groups that could gain or lose from have heated up lobbying campaigns both on and off the air, as the August recess is seen as the time to deliver messages. The Wall Street Journal reports on a few samples: "If you"re looking for savings, don"t come at us," said Tim Trysla, a senior medical device industry representative; "Attacking our community will not help get anyone covered," said Karen Ignagni, chief executive of lobbying group America"s Health Insurance Plans. Insurers have recently come under fire from Democrats. "What has fueled the lobbying surge is that President Barack Obama has left the details of the health overhaul to Congress. That means interest groups have plenty of decision-makers to badger. It also makes any legislation vulnerable to death by a thousand cuts," the Journal reports. For instance, lobbyists have successfully deterred Senators from a plan to tax health benefits, and a small hospital succeeded delaying action in the House (Adamy and Williamson, 8/5). This information was reprinted from kaiserhealthnews.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Health Policy Report, search the archives and sign up for email delivery at kaiserhealthnews.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):